University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
October 13, 2026

Members attending the meeting: Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Chen, Chun-Liang; Clark, Robert; Dray, Eloise; Gould, Georgianna; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Pugh, Jason; Shiio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

Guests Present: Rincon, Erica; Barlett, Emily.

Absent members: Cerecero, Jennifer; Dell, Shelbie; Gauduin, Marie Claire; Kautz, Tiffany; Salamango, Daniel.

1. **Panel Chair Announcement**
   The meeting was called to order at 11:03 a.m. by the IBC Chair, Dr. Yan Xiang.

2. **Confidentiality of Panel Proceedings and Conflict of Interest**
   The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

   Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. **Approval of minutes from the previous meeting**
   The Committee approved the minutes as written from the September 15, 2026, IBC meeting.
   Approved (17 voted to approve, 0 opposed, 0 abstained)

4. **Review of Approved Protocols-** The spreadsheet of approved protocols for FY2027 will be sent out for review in December 2026.

5. **Old Business –** None

6. **Educational Items –** NIH "Draft" Biosafety Policy

7. **Occupational Medicine-** As of October 1, 2026, there were ten cases of needlesticks, seven cases were by UT staff members, and three cases were by UT students. There were three cases of bloodborne exposures: one involved a student and two involved UT staff members. There was a case of a splash to the eye that

involved serum by a UT staff member. There was a percutaneous safety-pin stick case involving a UT staff member. You can now schedule your flu shot through MyChart for the Wellness 360 clinic. You can also call 210-567-2788 to schedule a flu shot.

8. Other – October is ABSA Biosafety Awareness Month

9. Review of EHS Assistant-
Review any issues with the EH&S Assistant program.

10. Meeting Reminder

The next meeting will be held on November 10, 2026.

Protocols for Review

11. Presentation, Discussion, and Voting on an Initial Protocol:
Protocol ID: 0000021872
Principal Investigator: Akopian, Armen; Center for Pain Therapeutics and Addiction Research
Title: Comprehensive functional phenotyping of Trigeminal neurons innervating temporomandibular joint (TMJ) tissues in male, female, and aged mice without TMJ disorders (TMJD).
Review Type: Full Committee Review
Form Type: Initial

Approved (17 voted to approve, 0 opposed, 0 abstained)

Initial application to work with mouse tissue and adenoviral vectors (p27.5-mScarlet+EF1-TPAsp+hTGFB3mp-F119-160-2 (plasmid 6114), p27.5-mScarlet+EF1-hTPAsp-mCCL2-F119-160-2 (plasmid6118), p27.5-mScarlet+NFkB-hTPAsp+hTGFB3mp-F119-160-2 (plasmid 6110)) at BSL-2 containment.

In vivo
Work with adenoviral vectors (p27.5-mScarlet+EF1-TPAsp+hTGFB3mp-F119-160-2 (plasmid 6114), p27.5-mScarlet+NFkB-hTPAsp+hTGFB3mp-F119-160-2 (plasmid 6110) in transgenic mice at ABSL-2 containment.
IACUC# IAMEND202600000418
Protocol does include the use of recombinant DNA.

This protocol was approved with clarification.

1. The committee requested additional clarification on the vectors.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Administration of recombinant or synthetic nucleic acid molecules into animals (e.g. transformed cells, vectors) III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

12. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 00000022644
Principal Investigator: Xu, Zhenming; Microbiology, Immunology, and Molecular Genetics
Title: N/A
Review Type: Full Review
Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with replication-incompetent Lentivirus, Retrovirus (ecotropic) MSCV, Vaccinia Virus (Pox virus), Candida albicans, Chlamydia trachomatis, vectors (pFuw, pLentiORF, pMIG), human cell lines (Daudi, MCF-7, MDA-MB-231, MDA-MB-468), and human blood at BSL-2 containment. Work with Eu-Myc mouse lymphoma primary cell lines, animal cell lines (D2A, E0771, Py8119), and mouse tissue bone marrow, vectors (pGex, pET), and E. coli (lab strains) at BSL-1 containment.

In vivo
Work with Eu-Myc mouse lymphoma primary cell lines, and animal cell lines (D2A, E0771, Py8119) in knock-out and transgenic mice at ABSL-1 containment.
IACUC# 16024X, #170219X, #20170219

Work with Vaccinia virus and human cell lines (Daudi, MCF-7) in knock-out and transgenic mice at ABSL-2 containment.
IACUC# 16024X, #170219X, #20170219
Protocol does include the use of recombinant DNA.

This protocol was approved with clarifications.

1. The committee requested clarification on the animal procedures.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Cloning and vector construction in bacteria and yeasts. III-E, III-F
Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

13. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 00000021885
Principal Investigator: Wickes, Brian; Microbiology, Immunology, and Molecular Genetics
Title: N/A
Review Type: Full Review
Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with fungal pathogens (including Bipolaris spp, Cunninghamella spp, Cryptococcus spp, Candida spp, Aspergillus spp, Epidermophyton spp, Exopiala (Wangiella) dermatitidis spp, Fonsecaea pedrosoi spp, Fusarium oxysporum spp, Mucor spp, Paecilomyces, Penicillium spp, Pseudallescheria boydii spp, Rhizopus spp, Rhiszomucor spp, Sporothrix schenckii spp, Stachybotrus atra spp, Torulopsis glabrata spp, Trichophyton spp, Zygomycetes species), Agrobacterium tumefaciens, and Ochronconis gallopavum at BSL-2 containment.
Work with lab strains of E. coli, yeast (Saccharomyces cerevisiae, Pichia angusta, Blastoschizomyces capitatus) at BSL-1 containment.
Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

14. Presentation, Discussion, and Voting on an Amendment Protocol:
Protocol ID: 00000022612
Principal Investigator: Pertsemlidis, Alexander; Greehey CCRI
Title: N/A
Review Type: Full Review
Form Type: Amendment

Approved (17 voted to approve, 0 opposed, 0 abstained)

Amendment application, to work with human cell lines (A549, Huvec), fibroblasts, and small extracellular vesicles (sEVs) at BSL-2 containment.

In vivo
Work with fibroblasts, A549, Huvec, HEK293, and sEVs in mice at ABSL-2 containment.
IACUC# IPROTO202600000056
Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3
Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

15. Presentation, Discussion, and Voting on a Renewal Protocol:
Protocol ID: 00000022645
Principal Investigator: Diogenes, Anibal; Endodontics
Title: Trigeminal afferents regulation of Apical Periodontitis development.
Review Type: Full Review
Form Type: Renewal

Approved (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with human cells (Apical papilla) at BSL-2 containment.

Work with mouse tissue, murine osteoblastic cells, and osteoclastic precursor macrophage cell line (raw264.7) at BSL-1 containment. Work with transgenic mouse strains (DTA-lox, Nav1.8 (SNS)-CreERT2, Parv (PV)-Cre, Trkc-CreERT2, CGRP-CreER, Advillin (AV)-CreERT2) at ABSL-1 containment.
IACUC# 20170053AR
Protocol does not include the use of recombinant DNA.

This protocol was approved with clarifications.
1. The committee requested clarification on how human cells are utilized in the lab projects.
2. The committee requested clarification on the procedures utilized to induce biological agents in research projects.
3. The committee requested clarification on how osteoblastic cells are utilized in the lab projects.
4. The committee requested clarification on how the core labs will be utilized with lab samples.

NIH Guidelines:
Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1
Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1
Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Adjourn: The meeting adjourned at 12:24 P.M.

Dr. Yan Xiang
Institutional Biosafety Committee Chair
University of Texas Health San Antonio

Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam